Quinazoline compound

PK139921AUndetermined Publication Date: 2009-01-17ASTRAZENECA UK LTD
0 Cites 0 Cited by

Patent Information

Application Number
PK199700826
Authority / Receiving Office
PK · PK
Patent Type
Applications
Current Assignee / Owner
Publication Date
2009-01-17
Patent Text Reader

Abstract

The invention concerns quinazoline compound of the formula 1 wherein n is 1, 2 or 3 and each R2 is independently halogeno, trifluoro methyl or (l-4C)alkyl; R3 is (1-4C)alkoxy; and R 1 is di-[(l-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-l-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1 -yl -(2-4C)alkoxy, 4-(l -4C)alky Ipiperazin-1-yl-(2-4C)alkoxy, imidazol-1 -yl-(2-4C)alkoxy, di-[(l-4C)alkoxy-(2-4C)alkyl]amino-(2-4C)alkoxy, thiamorpholino-(2-4C)alkoxy, 1 -oxothiamorpholino-(2-4C)alkoxy or 1,1 -dioxothiamorpholino-(2-4C)alkoxy, and wherein any of the above-mentioned R1 subsiituents comprising a CH2 (methylene) group which is not attached to a N or O atom optionally bears on said CH2 group a hydroxyl substituent; pharmaceutical composition containing it, and the use of the receptor tyrosine kinase inhibitory properties of the compound in the treatment of proliferative disease such as cancer.
Need to check novelty before this filing date? Find Prior Art